The US Food and Drug Administration has confirmed the approval of a new prostate cancer drug developed by Medivation and Astellas Pharma for men who have failed to respond to hormone therapy and chemotherapy. The drug, known as Xtandi, belongs to a new class of drugs known as androgen inhibitors and works by interfering in testosterone's ability to bind prostate cells together. The drug will reportedly cost (Dollar) 7,450 for a 30-day supply with analysts predicting that the ...Saturday, 1 September 2012
New Prostate Cancer Drug Developed by Medivation and Astellas Pharma Gets FDA Nod
The US Food and Drug Administration has confirmed the approval of a new prostate cancer drug developed by Medivation and Astellas Pharma for men who have failed to respond to hormone therapy and chemotherapy. The drug, known as Xtandi, belongs to a new class of drugs known as androgen inhibitors and works by interfering in testosterone's ability to bind prostate cells together. The drug will reportedly cost (Dollar) 7,450 for a 30-day supply with analysts predicting that the ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment